Night-time symptoms: A forgotten dimension of COPD

European Respiratory Review

Volumn 20, Issue 121, 2011, Pages 183-194

  Agusti, A ^a,b   Hedner, J ^e   Marin, J M ^c   Barbele F ^b,d   Cazzola, M ^f   Rennard, S ^g  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g Pulmonary and Critical Care Medical Center   (United States)

Author keywords

Burden; Chronic bronchitis; Emphysema; Pharmacotherapy; Sleep disturbance

Indexed keywords

ACLIDINIUM BROMIDE; IPRATROPIUM BROMIDE; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

AGE; ASTHMA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCADIAN RHYTHM; COGNITION; COMORBIDITY; COUGHING; DEPRESSION; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DYSPNEA; EPIDEMIOLOGICAL DATA; EVENING DOSAGE; HUMAN; LUNG FUNCTION; MORNING DOSAGE; MORTALITY; NIGHT SYMPTOM; OBESITY; OXYGEN THERAPY; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; QUALITY OF LIFE; REVIEW; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP PATTERN; SYMPTOM; WHEEZING;

BRONCHODILATOR AGENTS; CIRCADIAN RHYTHM; CONGRESSES AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; SLEEP; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 80052539830     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00004311     Document Type: Review

References (99)

1. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
2. American Thoracic Society, European Respiratory Society. Standards for the Diagnosis and Management of Patients with COPD. New York, American Thoracic Society; Lausanne, European Respiratory Society, 2004.
3. Parish JM. Sleep-related problems in common medical conditions. Chest 2009; 135: 563-572.
4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease, 2010.
5. Banks S, Dinges DF. Behavioural and physiological consequences of sleep restriction. J Clin Sleep Med 2007; 3: 519-528.
6. Balkin TJ, Rupp T, Picchioni D, et al. Sleep loss and sleepiness: current issues. Chest 2008; 134: 653-660.
7. Morselli L, Leproult R, Balbo M, et al. Role of sleep duration in the regulation of glucose metabolism and appetite. Best Pract Res Clin Endocrinol Metab 2010; 24: 687-702.
8. Knutson KL, Spiegel K, Penev P, et al. The metabolic consequences of sleep deprivation. Sleep Med Rev 2007; 11: 163-178.
9. Chaput JP, Despres JP, Bouchard C, et al. The association between sleep duration and weight gain in adults: a 6-year prospective study from the Quebec Family Study. Sleep 2008; 31: 517-523.
10. Patel SR, Ayas NT, Malhotra MR, et al. A prospective study of sleep duration and mortality risk in women. Sleep 2004; 27: 440-444.
11. Akerstedt T, Kecklund G, Gillberg M. Sleep and sleepiness in relation to stress and displaced work hours. Physiol Behav 2007; 92: 250-255.
12. Mezick EJ, Matthews KA, Hall M, et al. Intra-individual variability in sleep duration and fragmentation: associations with stress. Psychoneuroendocrinology 2009; 34: 1346-1354.
13. van den Berg JF, Knvistingh NA, Tulen JH, et al. Actigraphic sleep duration and fragmentation are related to obesity in the elderly: the Rotterdam Study. Int J Obes (Lond) 2008; 32: 1083-1090.
14. Mohsenin V. Sleep in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26: 109-116.
15. Mortola JP. Breathing around the clock: an overview of the circadian pattern of respiration. Eur J Appl Physiol 2004; 91: 119-129.
16. Collop NA, Salas RE, Delayo M, et al. Normal sleep and circadian processes. Crit Care Clin 2008; 24, 449-460
17. Appelberg J, Pavlenko T, Bergman H, et al. Lung aeration during sleep. Chest 2007; 131: 122-129.
18. Spengler CM, Shea SA. Endogenous circadian rhythm of pulmonary function in healthy humans. Am J Respir Crit Care Med 2000; 162: 1038-1046.
19. Calverley PM, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58: 855-860.
20. Phillipson EA, Sullivan CE, Read DJ, et al. Ventilatory and waking responses to hypoxia in sleeping dogs. J Appl Physiol 1978; 44: 512-520.
21. Phillipson EA, Murphy E, Kozar LF. Regulation of respiration in sleeping dogs. J Appl Physiol 1976; 40: 688-693.
22. Klink M, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest 1987; 91: 540-546.
23. Klink ME, Dodge R, Quan SF. The relation of sleep complaints to respiratory symptoms in a general population. Chest 1994; 105: 151-154.
24. Lewis CA, Fergusson W, Eaton T, et al. Isolated nocturnal desaturation in COPD: prevalence and impact on quality of life and sleep. Thorax 2009; 64: 133-138.
25. Cormick W, Olson LG, Hensley MJ, et al. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax 1986; 41: 846-854.
26. Valipour A, Lavie P, Lothaller H, et al. Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Med 2011; 12: 367-372.
27. Kinsman RA, Yaroush RA, Fernandez E, et al. Symptoms and experiences in chronic bronchitis and emphysema. Chest 1983; 83: 755-761.
28. Karachaliou F, Kostikas K, Pastaka C, et al. Prevalence of sleeprelated symptoms in a primary care population - their relation to asthma and COPD. Prim Care Respir J 2007; 16: 222-228.
29. Tsai CL, Brenner BE, Camargo CA Jr. Circadian-rhythm differences among emergency department patients with chronic obstructive pulmonary disease exacerbation. Chronobiol Int 2007; 24: 699-713.
30. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone ropionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6: 320-329.
31. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68: 1975-2000.
32. Price D, Small M, Milligan G. The prevalence and impact of nighttime symptoms in COPD patients - results from a crosssectional study in five European countries. Proceedings of the IV World Asthma and COPD Forum (Paris, France, April 30 to May 3, 2011).
33. Weitzenblum E, Chaouat A. Sleep and chronic obstructive pulmonary disease. Sleep Med Rev 2004; 8: 281-294.
34. Marrone O, Salvaggio A, Insalaco G. Respiratory disorders during sleep in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2006; 1: 363-372.
35. Owens RL, Malhotra A. Sleep-disordered breathing and COPD: the overlap syndrome. Respir Care 2010; 55: 1333-1344.
36. Becker HF, Piper AJ, Flynn WE, et al. Breathing during sleep in patients with nocturnal desaturation. Am J Respir Crit Care Med 1999; 159: 112-118.
37. Hudgel DW, Martin RJ, Capehart M, et al. Contribution of hypoventilation to sleep oxygen desaturation in chronic obstructive pulmonary disease. J Appl Physiol 1983; 55: 669-677.
38. White JE, Drinnan MJ, Smithson AJ, et al. Respiratory muscle activity during rapid eye movement (REM) sleep in patients with chronic obstructive pulmonary disease. Thorax 1995; 50: 376-382.
39. Scano G, Spinelli A, Duranti R, et al. Carbon dioxide responsiveness in COPD patients with and without chronic hypercapnia. Eur Respir J 1995; 8: 78-85.
40. Koo KW, Sax DS, Snider GL. Arterial blood gases and pH during sleep in chronic obstructive pulmonary disease. Am J Med 1975; 58: 663-670.
41. Mueller PT, Gomes MD, Viegas CA, et al. Systemic effects of nocturnal hypoxemia in patients with chronic obstructive pulmonary disease without obstructive sleep apnoea syndrome. J Bras Pneumol 2008; 34: 567-574.
42. Gilmartin GS, Tamisier R, Curley M, et al. Ventilatory, hemodynamic, sympathetic nervous system, and vascular reactivity changes after recurrent nocturnal sustained hypoxia in humans. Am J Physiol Heart Circ Physiol 2008; 295: H778-H785.
43. Tirlapur VG, Mir MA. Nocturnal hypoxemia and associated electrocardiographic changes in patients with chronic obstructive airways disease. N Engl J Med 1982; 306: 125-130.
44. McNicholas WT, Fitzgerald MX. Nocturnal deaths among patients with chronic bronchitis and emphysema. Br Med J (Clin Res Ed) 1984; 289: 878.
45. Gami AS, Somers VK. Implications of obstructive sleep apnoea for atrial fibrillation and sudden cardiac death. J Cardiovasc Electrophysiol 2008; 19: 997-1003.
46. Gami AS, Howard DE, Olson EJ, et al. Day-night pattern of sudden death in obstructive sleep apnoea. N Engl J Med 2005; 352: 1206-1214.
47. Smith J. Monitoring chronic cough: current and future techniques. Expert Rev Respir Med 2010; 4: 673-683.
48. Backhaus J, Junghanns K, Broocks A, et al. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res 2002; 53: 737-740.
49. Beck SL, Schwartz AL, Towsley G, et al. Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J Pain Symptom Manage 2004; 27: 140-148.
50. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
51. Weaver TE, Laizner AM, Evans LK, et al. An instrument to measure functional status outcomes for disorders of excessive sleepiness. Sleep 1997; 20: 835-843.
52. Stein KD, Jacobsen PB, Blanchard CM, et al. Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 2004; 27: 14-23.
53. Al-shair K, Kolsum U, Berry P, et al. Development, dimensions, reliability and validity of the novel Manchester COPD fatigue scale. Thorax 2009; 64: 950-955.
54. Theander K, Cliffordson C, Torstensson O, et al. Fatigue Impact Scale: its validation in patients with chronic obstructive pulmonary disease. Psychol Health Med 2007; 12: 470-484.
55. Bouchet C, Guillemin F, Hoang Thi TH, et al. Validation du questionnaire St Georges pour mesurer la qualite ́ de vie chez les insuffisants respiratoires chroniques [Validation of the St George's questionnaire for measuring the quality of life in patients with chronic obstructive pulmonary disease]. Rev Mal Respir 1996; 13: 43-46.
56. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001; 33: 337-343.
57. Nunes DM, Mota RM, de Pontes Neto OL, et al. Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung 2009; 187: 159-163.
58. Scharf SM, Maimon N, Simon-Tuval T, et al. Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6: 1-12.
59. Hynninen MJ, Pallesen S, Nordhus IH. Factors affecting health status in COPD patients with co-morbid anxiety or depression. Int J Chron Obstruct Pulmon Dis 2007; 2: 323-328.
60. Pokrzywinski RF, Meads DM, McKenna SP, et al. Development and psychometric assessment of the COPD and Asthma Sleep Impact Scale (CASIS). Health Qual Life Outcomes 2009; 7: 98.
61. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-654.
62. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043-2048.
63. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37: 264-272.
64. McNicholas WT, Calverley PM, Lee A, et al. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004; 23: 825-831.
65. Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1030-1036.
66. Martin RJ, Bartelson BL, Smith P, et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999; 115: 1338-1345.
67. Ryan S, Doherty LS, Rock C, et al. Effects of salmeterol on sleeping oxygen saturation in chronic obstructive pulmonary disease. Respiration 2010; 79: 475-481.
68. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750.
69. Terzano C, Petroianni A, Conti V, et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008; 102: 1701-1707.
70. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005; 99: 1511-1520.
71. Welte T, Metzenauer P, Hartmann U. Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD-a double-blind, randomised, controlled trial. Pulm Pharmacol Ther 2008; 21: 4-13.
72. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6: 17-25.
73. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009; 69: 549-565.
74. Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3: 1-11.
75. Zheng JP, Yang L, Wu YM, et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest 2007; 132: 1756-1763.
76. Make B, Hanania NA, ZuWallack R, et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/ albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005; 27: 531-542.
77. Kerwin E, Rennard SI, Gelb AF, et al. Twice-daily aclidinium bromide in COPD patients: nighttime symptoms and rescue medication use in ACCORD COPD I. Am J Respir Crit Care Med 2011; 183: A1592.
78. Fletcher EC, Levin DC. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. Chest 1984; 85: 6-14.
79. Goldstein RS, Ramcharan V, Bowes G, et al. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med 1984; 310: 425-429.
80. Clini E, Sturani C, Rossi A, et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20: 529-538.
81. McEvoy RD, Pierce RJ, Hillman D, et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomized controlled trial. Thorax 2009; 64: 561-656.
82. Pedrosa RP, Lima SG, Drager LF, et al. Sleep quality and quality of life in patients with hypertrophic cardiomyopathy. Cardiology 2010; 117: 200-206.
83. Lanier BQ, Nayak A. Prevalence and impact of nighttime symptoms in adults and children with asthma: a survey. Postgrad Med 2008; 120: 58-66.
84. Drewes AM, Svendsen L, Taagholt SJ, et al. Sleep in rheumatoid arthritis: a comparison with healthy subjects and studies of sleep/ wake interactions. Br J Rheumatol 1998; 37: 71-81.
85. Tachibana N, Howard RS, Hirsch NP, et al. Sleep problems in multiple sclerosis. Eur Neurol 1994; 34: 320-323.
86. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364: 656-665.
87. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
88. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
89. Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnoea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325-331.
90. Wertz DA, Pollack M, Rodgers K, et al. Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Ann Allergy Asthma Immunol 2010; 105: 118-123.
91. Sundberg R, Toren K, Franklin KA, et al. Asthma in men and women: treatment adherence, anxiety, and quality of sleep. Respir Med 2010; 104: 337-344.
92. Prescott E, Bjerg AM, Andersen PK, et al. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997; 10: 822-827.
93. Lee KK, Birring SS. Cough and sleep. Lung 2010; 188: Suppl. 1, S91-S94.
94. Jarjour NN, Busse WW. Cytokines in bronchoalveolar lavage fluid of patients with nocturnal asthma. Am J Respir Crit Care Med 1995; 152: 1474-1477.
95. Bates ME, Clayton M, Calhoun W, et al. Relationship of plasma epinephrine and circulating eosinophils to nocturnal asthma. Am J Respir Crit Care Med 1994; 149: 667-672.
96. Mackay TW, Wallace WA, Howie SE, et al. Role of inflammation in nocturnal asthma. Thorax 1994; 49: 257-262.
97. Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154: 1505-1510.
98. Panzer SE, Dodge AM, Kelly EA, et al. Circadian variation of sputum inflammatory cells in mild asthma. J Allergy Clin Immunol 2003; 111: 308-312.
99. Atanasov ST, Calhoun W. The relationship between sleep and asthma. Sleep Med Clin 2007; 2: 9-18.